Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
PALO ALTO, CA / ACCESS Newswire / November 17, 2026 / Bioz, Inc., the leading AI-powered platform for scientific research...
PALO ALTO, CA / ACCESS Newswire / November 17, 2026 / Bioz, Inc., the leading AI-powered platform for scientific research...
In a laboratory study, antiviral T-cells killed nearly 100% of human liver-derived cancer cells treated with CancerVax’s leading LNP-mRNA formulationLehi,...
DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undruggable...
TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix License supports...
The final close was led by Ackermans & van Haaren, with participation from additional new investors AbbVie Ventures and M...
A key strategic initiative combining AI-powered personalised nutrition and fitness, Premium subscriptions and a phased rollout across key marketsLONDON, Nov....
Cosentyx® (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹Approval marks 11th US indication for Cosentyx,...
AR1001 met the primary endpoint in the prespecified Monotherapy population, with a CDR-SB treatment difference of -0.44 points versus placebo...
AGC employee in cell therapy services suites An AGC employee works in cell therapy services suites on the Yokohama campus...
Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company...
Benefits of continuous lecanemab treatment in early Alzheimer’s disease accrue over time Lecanemab reduced the relative risk of progression to...
Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor...
Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional informationInitiated enrollment into GALACTIC registry...
CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population...
Ratutrelvir (COVID): Positive final Phase 2a results support further studies in PAXLOVID®-ineligible patients Tivoxavir marboxil (TXM, Influenza): Successful completion of...
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on...
Conference Call Scheduled for Today, November 16, at 5:00 p.m. ETLITTLETON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Precision Optics...
- Received FDA Type 2b feedback providing greater clarity on AEON's integrated biosimilar development strategy combining comparative analytical assessment, human...
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Recently published...
Eversense 365 now works with iLet, combining a year of accurate glucose monitoring with fully adaptive, automated insulin delivery to...